Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Technology
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Visual Stories
  • Reviews
  • Phone Reviews
  • Fitness Bands Reviews
  • Speakers Reviews
  • Find Cricket Statistics
Hindi
More
In the news
Vladimir Putin
United States of America
North Atlantic Treaty Organization
COVID-19
Russia-Ukraine crisis
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Technology
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Visual Stories
Reviews
Phone Reviews
Fitness Bands Reviews
Speakers Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / World News / Chinese drugmaker: Vaccine 79.3% effective in final tests
World

Chinese drugmaker: Vaccine 79.3% effective in final tests

Chinese drugmaker: Vaccine 79.3% effective in final tests
Written by Srijita Sen
(Sourced from PTI)
Dec 30, 2020, 05:06 pm 2 min read
Chinese drugmaker: Vaccine 79.3% effective in final tests

A Chinese drugmaker on Wednesday said its coronavirus vaccine was found to be 79.3% effective at preventing infection in preliminary data from the final round of testing, moving Beijing closer to possibly being able to fulfill its pledge to supply them to developing countries. More than one million health care workers and others there have received vaccines under emergency approval while testing was underway.

Details
Sinopharm is one of the Chinese developers creating vaccines

State-owned Sinopharm is one of at least four Chinese developers working on a vaccine for the disease that has killed 1.8 million people. Beijing Biological Products, the company's unit, said on its website that the vaccine is awaiting approval following the third and final stage of testing. However, the two-sentence announcement gave no information about side effects, conditions required to transport, or other details.

Details
The second vaccine from a Sinopharm unit

The Sinopharm vaccine relies on two doses, the company said, similar to Western-developed vaccines. It would be the second vaccine from a Sinopharm unit, following a separate candidate developed by the company's Wuhan Institute of Biological Products Ltd. Chinese producers have at least six possible vaccines in the final stage of clinical trials.

Details
Chinese developers testing vaccines in more than a dozen countries

Chinese developers are testing vaccines in more than a dozen countries, including Russia, Egypt, and Mexico. Few details have been released, leaving experts abroad wondering about effectiveness and side effects. While Western-developed vaccines must be kept frozen at temperatures as low as -70 degree Celsius, Chinese developers have said theirs can be stored at 2 to 8 degree Celsius.

Details
Health experts express concern about poorer countries

Even as western companies have started distributing their vaccines, some health experts have expressed concern too little will be available to poorer countries. China's government says it will ensure Chinese-developed vaccines are affordable for developing countries. Meanwhile, health experts say the certification process for the United States, Europe, Japan, and other developed countries might be too complex for Chinese vaccines to be used there.

Share this timeline
Facebook
Whatsapp
Twitter
Linkedin
Srijita Sen <br/><i>(Sourced from PTI)</i>
Srijita Sen
(Sourced from PTI)
Mail
Latest
Coronavirus
Related
Latest
Virat Kohli smashes this unique IPL record: Details here
Virat Kohli smashes this unique IPL record: Details here Sports
Union minister Ashwini Vaishnaw makes India's first 5G call
Union minister Ashwini Vaishnaw makes India's first 5G call Technology
IPL 2022, RR vs CSK: MS Dhoni elects to bat
IPL 2022, RR vs CSK: MS Dhoni elects to bat Sports
Hyundai will locally assemble IONIQ 5 EV for India
Hyundai will locally assemble IONIQ 5 EV for India Auto
Bollywood biggies invite legal trouble for endorsing tobacco brands
Bollywood biggies invite legal trouble for endorsing tobacco brands Entertainment
Coronavirus
COVID-19: India logs 3,303 new cases; 39 more deaths
COVID-19: India logs 3,303 new cases; 39 more deaths India
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man India
COVID-19 vaccine precautionary dose available for 18+ from April 10
COVID-19 vaccine precautionary dose available for 18+ from April 10 India
COVID-19 survivors at risk of developing serious blood clots: Study
COVID-19 survivors at risk of developing serious blood clots: Study Technology
COVID-19: India reports 1,660 new cases, 4,100 more deaths
COVID-19: India reports 1,660 new cases, 4,100 more deaths India
More News
Related
Biological E-manufactured J&J's single-dose COVID-19 vaccine in India by October
Biological E-manufactured J&J's single-dose COVID-19 vaccine in India by October India
Next News Article
Next News Article

Love World news?

Subscribe to stay updated.

World Thumbnail
India News Business News World News Politics News Sports News Technology News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Mukesh Ambani Indian Premier League (IPL) Karnataka Samsung Xiaomi West Bengal
Bihar Virat Kohli Rohit Sharma Haryana Narendra Modi Arvind Kejriwal Tamil Nadu Gujarat Yogi Adityanath YouTube
Instagram Hollywood News Uttar Pradesh Kerala Netflix Bollywood News Mamata Banerjee Maruti Suzuki Rahul Gandhi Elon Musk
Shah Rukh Khan Chelsea FC OPPO Akhilesh Yadav Indian Cricket Team Apple Manchester United Salman Khan Cryptocurrency OnePlus
Amitabh Bachchan ICC Women's World Cup Vivo India vs Sri Lanka
About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive IPL 2022 Schedule IPL 2022 Points Table Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2022